New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
NCT ID NCT06189391
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-phase study tests MK-1045, an immunotherapy that helps the immune system fight cancer, in 100 adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best tolerated dose, and see if the drug shows any signs of working. This is the first time MK-1045 is being given to people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hospital ( Site 0001)
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-••••
-
Fifth Medical Center of PLA General Hospital ( Site 0005)
RECRUITINGBeijing, Beijing Municipality, 100071, China
Contact Phone: •••-•••-••••
-
Fudan University Shanghai Cancer Center ( Site 0012)
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-••••
-
Henan Cancer Hospital ( Site 0009)
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-••••
-
Jiangxi Cancer Hospital ( Site 0007)
RECRUITINGNanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-••••
-
Shandong Cancer Hospital ( Site 0008)
ACTIVE_NOT_RECRUITINGJinan, Shandong, 250117, China
-
Shanghai East Hospital ( Site 0002)
RECRUITINGShanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-••••
-
Sichuan Cancer Hospital. ( Site 0018)
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-••••
-
Sun Yat-Sen University Cancer Center ( Site 0003)
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Xiamen University ( Site 0011)
RECRUITINGXiameng, Fujian, 361000, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Zhengzhou University ( Site 0006)
RECRUITINGZhengzhou, Henan, 451161, China
Contact Phone: •••-•••-••••
-
The First Hospital Of Jilin University ( Site 0014)
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-••••
-
The Fourth Hospital of Hebei Medical University. ( Site 0004)
RECRUITINGShijiazhuang, Hebei, 050035, China
Contact Phone: •••-•••-••••
-
Tianjin Medical University Cancer Institute and Hospital ( Site 0010)
ACTIVE_NOT_RECRUITINGTianjinc, Tianjin Municipality, 300060, China
-
Zhongshan Hospital,Fudan University ( Site 0013)
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.